Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivatrotamab in Relapsed/Recurrent Metastatic SCLC
NCT04750239Phase 2Terminated
- Sponsor
- Y-mAbs Therapeutics, Inc.
- Start
- Aug 2021
- Primary completion
- Apr 2022
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivatrotamab in small cell lung cancer (SCLC), sponsored by Y-mAbs Therapeutics, Inc.. Started Aug 2021; status: terminated.
02
Drugs
nivatrotamab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT04750239.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04750239.